PMID- 23994721
OWN - NLM
STAT- MEDLINE
DCOM- 20140709
LR  - 20151119
IS  - 1878-5492 (Electronic)
IS  - 0966-3274 (Linking)
VI  - 29
IP  - 1-4
DP  - 2013 Dec
TI  - Use of bortezomib to treat anti-HLA antibodies in renal transplant patients: a 
      single-center experience.
PG  - 7-10
LID - S0966-3274(13)00067-1 [pii]
LID - 10.1016/j.trim.2013.08.003 [doi]
AB  - Donor-specific human leukocyte antigen (HLA) antibodies (DSA) are associated with 
      decreased graft survival and may cause graft rejection. Bortezomib, a selective 
      inhibitor of the 26S proteasome developed to treat multiple myeloma, has been 
      used for its anti-plasma cell activity in patients undergoing transplantation. We 
      describe our experience with bortezomib used to reduce anti-HLA antibodies in 
      eight renal transplant patients. Patients received bortezomib (1.3mg/m(2)) on 
      days 1, 4, 8, and 11 beginning when antibodies were detected. It was used alone 
      in one patient and was complemented with plasmapheresis in five patients, with 
      IVIG in one patient, and with IVIG and plasmapheresis in another patient. De novo 
      DSA class II were detected in all eight patients and two also had DSA class I. 
      Antibodies were entirely eliminated in five (62.5%) patients 90 days after 
      treatment but only reduced in the other three (62.5%). Notably, they later 
      increased in one patient. Five (62.5%) patients had AMR, two (25%) had mixed 
      rejection, and one had no rejection. our results suggest that bortezomib is 
      effective for reducing DSA avoiding chronic graft injury.
CI  - (c) 2013.
FAU - Cicora, Federico
AU  - Cicora F
AD  - Renal Transplantation, Hospital Aleman, Pueyrredon 1640, C1118AAT Buenos Aires, 
      Argentina; Foundation for Research and Assistance in Renal Disease (FINAER), 503 
      No. 1947, B1897FYU Gonnet, La Plata, Buenos Aires, Argentina. Electronic address: 
      fcicora5@gmail.com.
FAU - Paz, Marta
AU  - Paz M
FAU - Mos, Fernando
AU  - Mos F
FAU - Roberti, Javier
AU  - Roberti J
LA  - eng
PT  - Journal Article
DEP - 20130829
PL  - Netherlands
TA  - Transpl Immunol
JT  - Transplant immunology
JID - 9309923
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Autoantibodies)
RN  - 0 (Boronic Acids)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Pyrazines)
RN  - 69G8BD63PP (Bortezomib)
SB  - IM
MH  - Adult
MH  - Allografts
MH  - Antineoplastic Agents/*administration & dosage
MH  - Autoantibodies/*blood
MH  - Boronic Acids/*administration & dosage
MH  - Bortezomib
MH  - Female
MH  - Graft Rejection/blood/*prevention & control
MH  - Graft Survival/*drug effects
MH  - Humans
MH  - Immunoglobulins, Intravenous/administration & dosage
MH  - *Kidney Transplantation
MH  - Male
MH  - Middle Aged
MH  - Plasmapheresis
MH  - Pyrazines/*administration & dosage
OTO - NOTNLM
OT  - Alloantibody
OT  - Bortezomib
OT  - HLA
OT  - Kidney
OT  - Proteasome inhibitor
OT  - Transplantation
EDAT- 2013/09/03 06:00
MHDA- 2014/07/10 06:00
CRDT- 2013/09/03 06:00
PHST- 2013/06/23 00:00 [received]
PHST- 2013/08/12 00:00 [revised]
PHST- 2013/08/12 00:00 [accepted]
PHST- 2013/09/03 06:00 [entrez]
PHST- 2013/09/03 06:00 [pubmed]
PHST- 2014/07/10 06:00 [medline]
AID - S0966-3274(13)00067-1 [pii]
AID - 10.1016/j.trim.2013.08.003 [doi]
PST - ppublish
SO  - Transpl Immunol. 2013 Dec;29(1-4):7-10. doi: 10.1016/j.trim.2013.08.003. Epub 
      2013 Aug 29.